Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
28.80
+1.24 (4.50%)
Oct 14, 2025, 3:31 PM EDT - Market open
Anbio Biotechnology Revenue
In the year 2024, Anbio Biotechnology had annual revenue of $8.19M with 21.95% growth. Anbio Biotechnology had revenue of $2.34M in the half year ending December 31, 2024, a decrease of -59.05%.
Revenue (ttm)
$8.19M
Revenue Growth
+21.95%
P/S Ratio
142.40
Revenue / Employee
$303,154
Employees
27
Market Cap
1.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.19M | 1.47M | 21.95% |
| Dec 31, 2023 | 6.71M | -16.83M | -71.49% |
| Dec 31, 2022 | 23.54M | 19.12M | 431.67% |
| Dec 31, 2021 | 4.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNNNN News
- 4 days ago - Anbio Biotechnology's Hype And Hard Approvals Suggest A Stretched Valuation - Seeking Alpha
- 2 months ago - Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System - GlobeNewsWire
- 5 months ago - Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions - GlobeNewsWire
- 8 months ago - U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
- 8 months ago - Anbio Biotechnology Announces Closing of Initial Public Offering - GlobeNewsWire
- 8 months ago - Anbio Biotechnology Announces Pricing of Initial Public Offering - GlobeNewsWire
- 10 months ago - U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings - Seeking Alpha
- 10 months ago - Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha